Skip to main content
. 2018 Nov 30;21(3):348–359. doi: 10.1093/neuonc/noy200

Fig. 3.

Fig. 3

Preexisting CTL responses against the 4 peptides selected for PPV (A) or against a mix of the control viral epitope peptides consisting of cytomegalovirus, Epstein–Barr virus, and influenza virus (B) in the patients of the 67 SART2-93(−) group vs those of the 21 SART2-93(+) group. Preexisting IgG responses against the 4 selected peptides for PPV (C), all the 12 HLA-A24–restricted peptides used in this study (D), 12 HLA-A2–restricted CTL peptides (E), or 5 HLA-A3 superfamily (A3, A11, A31, A33)–restricted CTL peptides (F) in these 2 groups, respectively.